WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

The Tracker / July 2026 / K260566

510(k) cleared

SMARTVERTIGO Vestibular Assessment System

VertigoDx, Inc. · Jul 30, 2026 · K260566

FDA cleared the SMARTVERTIGO Vestibular Assessment System from VertigoDx, Inc. on Jul 30, 2026 under K260566, a traditional 510(k). The device falls under product code GWN, Nystagmograph, regulated at 21 CFR 882.1460 as a Class 2 device. The review panel was Neurology.

FDA logged the submission as received on Feb 19, 2026. The decision came 161 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

This is the only decision on file for VertigoDx, Inc. in the last 12 months of the tracker.

Questions & Answers

What did FDA clear under K260566?

K260566 is the FDA 510(k) for SMARTVERTIGO Vestibular Assessment System, submitted by VertigoDx, Inc.. FDA's decision date was Jul 30, 2026, under product code GWN (Nystagmograph).

Who makes the SMARTVERTIGO Vestibular Assessment System?

VertigoDx, Inc., based in Wilmington, DE, is the applicant of record for K260566.

How long did the K260566 review take?

FDA received the submission on Feb 19, 2026 and issued its decision on Jul 30, 2026, 161 days later.

← All decisions in July 2026